ArticleJournal of clinical medicine2020
Torquetenovirus Serum Load and Long-Term Outcomes in Renal Transplant Recipients.
Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Torque teno virus load as marker of rejection and infection in solid organ transplantation - A systematic review and meta-analysis.Reviews in medical virology · 2023Pooled it
- Trial
- Torque teno virus viral load and hospitalisation for infections in long-term kidney transplant recipients: a single-centre prospective cohort study.BMC nephrology · 2026Article
- Torque Teno Virus as a Biomarker for Infection Risk in Kidney Transplant Recipients: A Machine Learning-Enabled Cohort Study.Infectious disease reports · 2025Article
- Torque Teno Virus: A Promising Biomarker in Kidney Transplant Recipients.International journal of molecular sciences · 2024Article
- High-Density Lipoprotein Particles and Torque Teno Virus in Stable Outpatient Kidney Transplant Recipients.Viruses · 2024Article
- Torquetenovirus from bronchoalveolar lavage fluid as a biomarker for lung infection among immunocompromised hosts.Biomarkers in medicine · 2024Article
- Dynamics of torque teno virus load in kidney transplant recipients with indication biopsy and therapeutic modifications of immunosuppression.Frontiers in medicine · 2024Article
- Article
- Article
- Article
- Observational
- Torque Teno Virus Load Predicts Opportunistic Infections after Kidney Transplantation but Is Not Associated with Maintenance Immunosuppression Exposure.Biomedicines · 2023Article
- Understanding torquetenovirus (TTV) as an immune marker.Frontiers in medicine · 2023Review
- Torquetenovirus viral load is associated with anti-spike antibody response in SARS-CoV-2 mRNA BNT162b2 vaccinated kidney transplant patients.Clinical transplantation · 2022Article
- High torque tenovirus (TTV) load before first vaccine dose is associated with poor serological response to COVID-19 vaccination in lung transplant recipients.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2022Article
- Article
- Promises of Big Data and Artificial Intelligence in Nephrology and Transplantation.Journal of clinical medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Following transplantation, patients must take immunosuppressive medication for life. Torquetenovirus (TTV) is thought to be marker for immunosuppression, and TTV-DNA levels after organ transplantation have been investigated, showing high TTV levels, associated with increased risk of infections, and low TTV levels associated with increased risk of rejection. However, this has been investigated in studies with relatively short follow-up periods. We hypothesized that TTV levels can be used to assess long term outcomes after renal transplantation. Serum samples of 666 renal transplant recipients were tested for TTV DNA. Samples were taken at least one year after renal transplantation, when TTV levels are thought to be relatively stable. Patient data was reviewed for graft failure, all-cause mortality and death due to infectious causes. Our data indicates that high TTV levels, sampled more than one year post-transplantation, are associated with all-cause mortality with a hazard ratio (HR) of 1.12 (95% CI, 1.02-1.23) per log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.